$0.59
+1.83%Sep 18, 2026, 23:00 UTC
Humacyte, Inc. (HUMA) shares closed at $0.59, up 2.23% from the previous close.
Source:Sep 9, 2026, 12:00 UTC
The U.S. Food and Drug Administration authorized Humacyte to extend the expiration dating period for its Symvess product from 18 months to 36 months when stored refrigerated at 2°C to 8°C.
Source:Aug 12, 2026, 00:00 UTC
Humacyte, Inc. reported Q2 2026 revenue of $0.4 million and a net loss of $36.8 million, with diluted EPS of -$0.16.
Aug 5, 2026, 23:01 UTC
Humacyte, Inc. (HUMA) shares rose 2.33% to close at $0.73 in the recent trading session.
Source:Jul 27, 2026, 12:00 UTC
Humacyte announced that the FDA accepted its IND application for a first-in-human clinical study of CTEV for coronary artery bypass grafting.
Source:Jun 11, 2026, 00:56 UTC
Humacyte, Inc. commenced an underwritten public offering of its common stock.